Soliris approved in China for the treatment of adults with refractory generalised myasthenia gravis

eAwazMedicine

London – Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement inhibitor approved for the treatment of gMG in China. The approval by the National Medical Products Administration (NMPA) in China was based on comprehensive results from the Phase III …

AstraZeneca showcases scientific talks of haematological conditions at EHA 2023

eAwazHealth

Pivotal ALPHA Phase III trial results will show benefit of danicopan, Alexion’s first-in- class Factor D inhibitor, in improving clinically significant extravascular haemolysis while allowing patients with PNH to remain on standard of care treatment Calquence data will reinforce role as a preferred treatment option for chronic lymphocytic leukaemia and mantle cell lymphoma Interim clinical data will show promise of …